SCHEMBL4850007

SCHEMBL4850007

O=C1[N]C(=O)c2c(O)cccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 4/20 0.56
MAPT P10636 8/20 0.54
ALDH1A1 P00352 5/20 0.54
TDP1 Q9NUW8 5/20 0.54
ALOX15 P16050 4/20 0.54
HSD17B10 Q99714 4/20 0.54
MAPK1 P28482 4/20 0.54
HPGD P15428 3/20 0.54
TSHR P16473 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MAOB P27338 2/20 0.54
LMNA P02545 1/20 0.54
HTT P42858 1/20 0.54
KMT2A Q03164 8/20 0.50
MEN1 O00255 7/20 0.50
KDM4E B2RXH2 5/20 0.50
RECQL P46063 5/20 0.50
USP2 O75604 4/20 0.50
CYP3A4 P08684 4/20 0.50
AURKA O14965 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2961474 0.83 MAOA (0.56) MAOAMAPTALDH1A1TDP1ALOX15
SCHEMBL10621855 0.74 HDAC4 (0.47) MAPTALDH1A1TDP1HSD17B10MAPK1
SCHEMBL3375220 0.74 CA2 (0.46) MAPTALDH1A1LMNAIDO1CA1
SCHEMBL5858478 0.74 MAPT (0.50) MAOAMAPTALDH1A1TDP1ALOX15
SCHEMBL7222595 0.74 ADORA2A (0.50) MAOAMAPTALDH1A1TDP1HSD17B10
SCHEMBL2884290 0.74 CA1 (0.46) ALDH1A1MAPK1TSHRSMN1; SMN2KMT2A
SCHEMBL9781818 0.74 CES1 (0.38) MAPTALDH1A1HSD17B10TSHRKDM4E
SCHEMBL7930862 0.74 ALDH1A1 (0.55) MAPTALDH1A1TDP1ALOX15HSD17B10
SCHEMBL7584603 0.74 PDCD1 (0.43) MAOAMAPTALDH1A1HPGDMAOB
SCHEMBL3642843 0.72 PGAM1 (0.40) MAOAMAPTALDH1A1TDP1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005370-A1 MOLECULAR GLASSES WITH FUNCTIONALIZABLE GROUPS HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE (CA) 2014-01-02 US claimed
EP-1347463-B1 Novel electrically conductive polymer, sensor using the same, and method for detecting target molecule using the sensor SAMSUNG ELECTRONICS CO LTD (KR) 2013-05-29 EP claimed
US-7341759-B2 Electrically conductive polymer, sensor using the same, and method for detecting target molecule using the sensor SAMSUNG ELECTRONICS CO., LTD. (KR) 2008-03-11 US claimed
US-6987164-B2 Electrically conductive polymer, sensor using the same, and method for detecting target molecule using the sensor SAMSUNG ELECTRONICS CO., LTD. (KR) 2006-01-17 US claimed
US-20050208579-A1 Novel electrically conductive polymer, sensor using the same, and method for detecting target molecule using the sensor CHA JUN-HOE 2005-09-22 US claimed
EP-1343494-A4 TETRAPARTATE PRODRUGS ENZON INC (US) 2005-08-03 EP claimed
JP-2004518776-A 2004-06-24 JP claimed
US-20030187182-A1 Novel electrically conductive polymer, sensor using the same, and method for detecting target molecule using the sensor SAMSUNG ELECTRONICS CO., LTD. (KR) 2003-10-02 US claimed
EP-1347463-A2 Novel electrically conductive polymer, sensor using the same, and method for detecting target molecule using the sensor Samsung Electronics Co., Ltd. (KR) 2003-09-24 EP claimed
EP-1343494-A2 TETRAPARTATE PRODRUGS ENZON, INC. (US) 2003-09-17 EP claimed
WO-2002043663-A2 TETRAPARTATE PRODRUGS ENZON, INC. (US) 2002-06-06 WO claimed
EP-3463308-B1 FORMULATIONS OF POLYALKYLENE OXIDE-ASPARAGINASE AND METHODS OF MAKING AND USING THE SAME SERVIER IP UK LTD (GB) 2021-12-01 EP disclosed
EP-3463308-A2 FORMULATIONS OF POLYALKYLENE OXIDE-ASPARAGINASE AND METHODS OF MAKING AND USING THE SAME Servier IP UK Limited (GB) 2019-04-10 EP disclosed
WO-2018017190-A2 FORMULATIONS OF POLYALKYLENE OXIDE-ASPARAGINASE AND METHODS OF MAKING AND USING THE SAME BAXALTA INCORPORATED (US) 2018-01-25 WO disclosed
CN-101680039-B Enzyme anti-cancer treatment 希格马托罕见疾病有限公司 2016-08-24 CN disclosed
WO-1999067192-A2 PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND α,β-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-12-29 WO disclosed
EP-0946478-A1 PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES, OXIMES, AMINES AND HYDROXAMIC ACID COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1999-10-06 EP disclosed
WO-1999031491-A1 METHOD AND REAGENTS FOR THE QUANTIFICATION OF SOLID-PHASE REACTIONS USING FLUORINE NMR AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-06-24 WO disclosed
US-5856560-A REACTING ACYL CYANIDE BENZENE COMPOUND WITH AN ALCOHOL; THEN AN HYDROXYLAMINE; METHYLATION BASF AKTIENGESELLSCHAFT (DE) 1999-01-05 US disclosed
WO-1998029376-A1 PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES, OXIMES, AMINES AND HYDROXAMIC ACID COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140005370-A1 MOLECULAR GLASSES WITH FUNCTIONALIZABLE GROUPS GNG2, GDI1, F12 MAOA 3871/4885MAPT 1554/4885ALDH1A1 2637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.